Trial record 1 of 1 for:    strive anti-jcv
Previous Study | Return to List | Next Study

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients (STRIVE)

This study is currently recruiting participants.
Verified August 2012 by Biogen Idec
Sponsor:
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT01485003
First received: December 1, 2011
Last updated: September 12, 2013
Last verified: August 2012
  Purpose

The purpose of the study is to find out if there are any assessments that might predict whether or not patients receiving Tysabri will remain free of disease (that is, without relapses, worsened disability, and/or lesions on brain magnetic imaging [MRI] scans) and how effective Tysabri is at keeping patients who are in the early stages of RRMS free of disease.


Condition
Relapsing-remitting Multiple Sclerosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing -Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients.

Resource links provided by NLM:


Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Proportion of patients who are overall disease activity-free [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
  • Proportion of patients who are clinical disease activity-free [ Time Frame: Month 48 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identification of baseline prognostic factors that predict overall disease-free status [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly prognostic factors that predict overall disease-free status [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
  • Clinical disease-free status [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Identification of baseline prognostic factors that predict clinical disease-free status [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly prognostic factors that predict clinical disease-free status [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Annualized Relapse Rate (ARR) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Sustained EDSS progression [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Sustained EDSS improvement [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T2 measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T1 measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T1 with Gadolinium-enhancing measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI brain atrophy measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Low Contrast Visual Acuity assessment [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Cognitive impairment as measured with the Symbol Digit Modalities Test (SDMT) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Capacity for work as measured by the Work Productivity and Activity Impairment (WPAI) questionnaire [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Quality of Life as measured by the Multiple Sclerosis Impact Scale (MSIS-29) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

Patients with relapsing-remitting multiple sclerosis (RRMS) presenting to sponsor selected neurology offices in the US who meet inclusion & exclusion criteria.

Criteria

Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
  • Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria [Polman et al., 2011]).
  • <3 year disease duration.
  • Must have an EDSS score from 0 to 4.0, inclusive.
  • Anti-JCV antibody negative test at Screening Visit
  • Must satisfy the approved therapeutic indications for Tysabri.
  • Must be treatment-naïve to disease-modifying therapy (DMT) or have been treated with a single DMT (including Avonex, Betaseron, Rebif, Copaxone, Extavia, or Gilenya) for ≤12 months total prior to date of informed consent.
  • Decision to treat with Tysabri must precede enrollment.

Exclusion Criteria:

  • Any prior treatment with Tysabri.
  • Anti-JCV antibody positive at any timepoint prior to the Screening Visit.
  • Contraindications to treatment with Tysabri as described in the US Prescribing Information.
  • History of PML or other opportunistic infections, or an increased risk for such infections.
  • History of diagnosis of Primary Progressive Multiple Sclerosis [PPMS] and/or Secondary Progressive Multiple Sclerosis [SPMS].
  • Receiving immunomodulatory or immunosuppressive therapy.
  • Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).
  • Immunocompromised at the time of enrollment.
  • Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
  • Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.
  • Inability to comply with study requirements.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01485003

Contacts
Contact: Medical Director strivestudy@biogenidec.com

  Hide Study Locations
Locations
United States, Alabama
Research Site Recruiting
Birmingham, Alabama, United States
United States, Arizona
Research Site Recruiting
Glendale, Arizona, United States
Research Site Not yet recruiting
Phoenix, Arizona, United States
Research Site Recruiting
Tempe, Arizona, United States
United States, California
Research Site Recruiting
Berkeley, California, United States
Research Site Not yet recruiting
LA, California, United States
Research Site Recruiting
La Jolla, California, United States
Research Site Recruiting
Los Angeles, California, United States
Research Site Recruiting
Newport Beach, California, United States
Research Site Recruiting
Sacramento, California, United States
Research Site Recruiting
Torrance, California, United States
United States, Colorado
Research Site Recruiting
Aurora, Colorado, United States
Research Site Recruiting
Ft. Collins, Colorado, United States
United States, Delaware
Research Site Recruiting
Newark, Delaware, United States
United States, District of Columbia
Research Site Recruiting
DC, District of Columbia, United States
Research Site Recruiting
Washington, District of Columbia, United States
United States, Florida
Research Site Recruiting
Gainesville, Florida, United States
Research Site Not yet recruiting
Hollywood, Florida, United States
Research Site Not yet recruiting
Jacksonville, Florida, United States
Research Site Recruiting
Miami, Florida, United States
United States, Georgia
Research Site Recruiting
Atlanta, Georgia, United States
United States, Illinois
Research Site Recruiting
Barrington, Illinois, United States
Research Site Recruiting
Champaign, Illinois, United States
Research Site Recruiting
Lake Barrington, Illinois, United States
Research Site Recruiting
Peoria, Illinois, United States
United States, Indiana
Research Site Recruiting
Indianapolis, Indiana, United States
United States, Iowa
Research Site Not yet recruiting
Des Moines, Iowa, United States
United States, Kansas
Research Site Recruiting
Overland Park, Kansas, United States
United States, Kentucky
Research Site Recruiting
Lexington, Kentucky, United States
Research Site Recruiting
Louisville, Kentucky, United States
United States, Louisiana
Research Site Not yet recruiting
New Orleans, Louisiana, United States
Research Site Not yet recruiting
Shreveport, Louisiana, United States
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States
Research Site Recruiting
Lexington, Massachusetts, United States
Research Site Recruiting
Worcester, Massachusetts, United States
United States, Michigan
Research Site Not yet recruiting
Detroit, Michigan, United States
Research Site Recruiting
East Lansing, Michigan, United States
United States, Nebraska
Research Site Recruiting
Lincoln, Nebraska, United States
United States, New York
Research Site Recruiting
Latham, New York, United States
Research Site Recruiting
New York, New York, United States
Research Site Recruiting
Patchogue, New York, United States
Research Site Recruiting
Plainview, New York, United States
Research Site Not yet recruiting
Stony Brook, New York, United States
Research Site Recruiting
White Plains, New York, United States
United States, North Carolina
Research Site Recruiting
Advance, North Carolina, United States
Research Site Recruiting
Winston-Salem, North Carolina, United States
United States, North Dakota
Research Site Recruiting
Grand Forks, North Dakota, United States
United States, Ohio
Research Site Not yet recruiting
Canton, Ohio, United States
Research Site Recruiting
Cleveland, Ohio, United States
Research Site Recruiting
Dayton, Ohio, United States
Research Site Recruiting
Gahanna, Ohio, United States
Research Site Recruiting
Uniontown, Ohio, United States
United States, Oregon
Research Site Recruiting
Portland, Oregon, United States
United States, Pennsylvania
Research Site Recruiting
Abington, Pennsylvania, United States
Research Site Not yet recruiting
Hershey, Pennsylvania, United States
United States, Tennessee
Research Site Not yet recruiting
Knoxville, Tennessee, United States
United States, Texas
Research Site Not yet recruiting
Austin, Texas, United States
Research Site Recruiting
Round Rock, Texas, United States
United States, Utah
Research Site Recruiting
Salt Lake City, Utah, United States
United States, Virginia
Research Site Recruiting
Newport News, Virginia, United States
Research Site Recruiting
Norfolk, Virginia, United States
United States, Washington
Research Site Recruiting
Seattle, Washington, United States
Research Site Recruiting
Tacoma, Washington, United States
Sponsors and Collaborators
Biogen Idec
  More Information

No publications provided

Responsible Party: Biogen Idec
ClinicalTrials.gov Identifier: NCT01485003     History of Changes
Other Study ID Numbers: 101MS407
Study First Received: December 1, 2011
Last Updated: September 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014